Overview

DIATOR-Diabetes Intervention With Atorvastatin

Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator. In this study the effects of 80 mg atorvastatin per day on preservation of beta-cell function in recent onset type 1 diabetes were studied, as determined by stimulated C-peptide levels.
Phase:
Phase 1
Details
Lead Sponsor:
Profil Institut für Stoffwechselforschung GmbH
Collaborator:
Pfizer
Treatments:
Atorvastatin
Atorvastatin Calcium